Currently, the SARC031 trial is evaluating combined MEK/mTOR inhibition (NCT03433183), further emphasizing the need for trials that combine inhibitors with preclinical justification in MPNST. Here, MTOR is linked to malignant peripheral nerve sheath tumor.